Aldeyra The Total Liabilities

Latest as of June 2026: $9.66 Million USD

Aldeyra The total liabilities. Based on the latest financial reports, Aldeyra The (ALDX) has total liabilities worth $9.66 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Aldeyra The to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Aldeyra The (2011–2025)

Total liabilities of Aldeyra The from 2011 to 2025. This chart illustrates how Aldeyra The's total liabilities have evolved over time, based on quarterly financial data.

Aldeyra The Competitors by Total Liabilities

The table below lists competitors of Aldeyra The ranked by their total liabilities.

Company Country Total Liabilities
Bedmutha Industries Limited
NSE:BEDMUTHA
India Rs-1.52 Billion
Delticom AG
F:DEX
Germany €161.18 Million
German High Street Properties A/S Class B
CO:GERHSP
Denmark Dkr37.09 Million
Almondz Global Securities Limited
NSE:ALMONDZ
India Rs-2.93 Billion
Enogia SAS
PA:ALENO
France €16.86 Million
Structural Monitoring Systems Plc
AU:SMN
Australia AU$11.13 Million
Thai Textile Industry Public Company Limited
BK:TTI
Thailand ฿595.13 Million
Krungthai Car Rent and Lease Public Company Limited
BK:KCAR
Thailand ฿2.51 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Aldeyra The's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Aldeyra The's balance sheet.

Liquidity & Leverage Metrics

Aldeyra The Total Liabilities Ratios Explained

Aldeyra The total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 4.91 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.25 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aldeyra The's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aldeyra The (2011–2025)

The table below shows the annual total liabilities of Aldeyra The from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 $27.81 Million -17.24%
2024-12-31 $33.60 Million +17.77%
2023-12-31 $28.53 Million -5.78%
2022-12-31 $30.28 Million +10.52%
2021-12-31 $27.40 Million +14.92%
2020-12-31 $23.84 Million -13.09%
2019-12-31 $27.44 Million +223.80%
2018-12-31 $8.47 Million +85.25%
2017-12-31 $4.57 Million +29.29%
2016-12-31 $3.54 Million +6.36%
2015-12-31 $3.33 Million +32.90%
2014-12-31 $2.50 Million +17.60%
2013-12-31 $2.13 Million -92.16%
2012-12-31 $27.13 Million +946.16%
2011-12-31 $2.59 Million --

About Aldeyra The

NASDAQ:ALDX USA Biotechnology
Market Cap
$37.44 Million
Market Cap Rank
#22762 Global
#5011 in USA
Share Price
$0.62
Change (1 day)
+6.41%
52-Week Range
$0.56 - $5.62
All Time High
$14.85
About

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more